We serve Chemical Name:Elacridar (hydrochloride) CAS:143851-98-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Elacridar (hydrochloride)
CAS.NO:143851-98-3
Synonyms:UNII-NX2BHH1A5B;Elacridar HCl;Elacridar hydrochloride;Elacridar hydrochloride (USAN);Elacridar (hydrochloride)
Molecular Formula:C34H34ClN3O5
Molecular Weight:600.10400
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:701.6ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:92.89000
Exact Mass:599.21900
LogP:6.37310
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like UNII-NX2BHH1A5B chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Elacridar (hydrochloride) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Elacridar hydrochloride (USAN) Use and application,UNII-NX2BHH1A5B technical grade,usp/ep/jp grade.
Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. Elacridar (hydrochloride) manufacturer Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. Elacridar (hydrochloride) supplier We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. Elacridar (hydrochloride) vendor Secretary of Health Francisco Duque said authorities are working with the Chinese embassy to respectfully handle the remains of the man while following international protocol to contain the disease. Elacridar (hydrochloride) factory We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.